Tech Company Financing Transactions

Engrail Therapeutics Funding Round

Engrail Therapeutics secured a $157 million Series B funding round on 3/19/2024. Investors included F-Prime Capital, Forbion Capital Partners and Norwest Venture Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

12750 High Bluff Dr. 190
San Diego, CA 92130
USA

Phone

Undisclosed

Website

www.engrail.com

Email Address

[email protected]

Overview

Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Vikram Sudarsan

        

Chief Financial Officer

Rex Bosen

        

Chief Scientific Officer

Stephen Cunningham

        

VP - Bus. Development

Camilla Gomiero

        

VP - Bus. Development

Eve Taylor

        

VP - Bus. Development

Anil Vootkur

        

Browse more venture capital transactions:

Prev: 3/19/2024: Ingrid venture capital transaction
Next: 3/19/2024: Keyring Network venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary